Pharmabiz7h
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
FDA assigns PDUFA target action date of April 29, 2025CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABEO) today ...
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of ...
dermatologyadvisor16h
FDA to Review Resubmitted Dupilumab sBLA for Chronic Spontaneous Urticaria
The FDA has accepted for review the resubmitted sBLA for dupilumab for the treatment of chronic spontaneous urticaria.
The Pharma Letter18h
FDA signals progress on the western front for belantamab mafodotin
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab ...
GSK eyes up combo approval for previously withdrawn myeloma drug
The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.